Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unresectable Hepatocellular Carcinoma × Bevacizumab × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 422 Carcinoma, Non-Small-Cell Lung 213 Breast Neoplasms 178 Ovarian Neoplasms 153 Glioblastoma 143 Neoplasms 118 Carcinoma, Hepatocellular 106 Rectal Neoplasms 104 Colonic Neoplasms 101 Neoplasm Metastasis 95 Brain Neoplasms 90 Lung Neoplasms 79 Fallopian Tube Neoplasms 73 Carcinoma, Renal Cell 66 Glioma 63 Pancreatic Neoplasms 50 Gliosarcoma 41 Melanoma 40 Liver Neoplasms 37 Uterine Cervical Neoplasms 36 Adenocarcinoma of Lung 36 Stomach Neoplasms 34 Recurrence 33 Astrocytoma 28 Endometrial Neoplasms 25 Triple Negative Breast Neoplasms 24 Carcinoma, Ovarian Epithelial 24 Esophageal Neoplasms 21 Kidney Neoplasms 20 Oligodendroglioma 18

Interventions

tremelimumab 1 durvalumab 1 atezolizumab 1 Therapeutics 1 Immunotherapy 1 Bumetanide 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06117891 2025-11-12

REFINE-IO

Bayer

Gastrointestinal

Unresectable Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡